diorasis

DIORASIS THERAPEUTICS

GENE THERAPY FOR GLAUCOMA

Glaucoma

Glaucoma is the leading cause of irreversible blindness, affecting about 3 million Americans and 80 million people worldwide. It is mainly caused by high pressure inside the eye.

Our Technology

Our disease modifying gene therapy targets a single administration for long-term, potentially life-long, lowering of intraocular pressure (IOP) in most glaucoma patients with an innovative first-in-class mechanism of action.

Our Team

Scientific leaders and industry innovators, with deep-experience in glaucoma and ophthalmology gene therapies, seeking to change the treatment paradigm for patients getting blind from glaucoma around the world.

Glaucoma

Glaucoma is the leading cause of irreversible
blindness, affecting about 3 million Americans and 80 million people worldwide. It is mainly caused by high pressure inside the eye.

Our Technology

Our disease modifying gene therapy targets a
single administration for long-term, potentially life-long, lowering of intraocular pressure (IOP) in most glaucoma patients with an innovative first-in-class mechanism of action.

Our Team

Scientific leaders and industry innovators, with
deep-experience in glaucoma and ophthalmology gene therapies, seeking to change the treatment paradign for patients getting blind from glaucoma around the world.

ABOUT US

DIORASIS THERAPEUTICS

Diorasis Therapeutics is a pre-clinical stage biotech company developing innovative ophthalmology products for common diseases aspiring to prevent blindness. The lead-compound is a first-in-class disease-modifying gene-agnostic gene therapy for normalizing outflow facility in the trabecular meshwork and decreasing intraocular pressure in patients with open angle glaucoma.

aBOUT gLaUCOMA

WHAT IS GLAUCOMA?

Glaucoma is a gradually progressive eye diseases that damages the optic nerve. The optic nerve transfers visual information from the eye to the brain. Damage to the optic nerve from glaucoma results in loss of vision and eventually complete irreversible blindness.

Our Technology

Focus on tissue Plasminogen Activator

Upregulating an enzymatically inactive tissue plasminogen activator (EI-tPA) variant in the TM to improve outflow facility and decrease IOP after a single administration by modulating extracellular matrix turnover
Scroll to Top